Mutations Targeted by Nous-209 Immunotherapy Occur Early in Lynch Syndrome Carriers' Precancer Lesions with Microsatellite Instability.
Veröffentlicht: 2026-05-11
Cancer prevention research (Philadelphia, Pa.)
MediLens Indexiert: 2026-05-12
This study characterizes precancerous colorectal lesions in Lynch syndrome carriers and evaluates the potential of Nous-209 immunotherapy for cancer prevention. Among 50 adenomas and 12 advanced adenomas from 26 carriers, 83% of advanced adenomas and 58% of adenomas were found to be MMR-deficient...
Auf PubMed lesen